1. Hall HI, An Q, Tang T, et al; Centers for Disease Control and Prevention (CDC). Prevalence of diagnosed and undiagnosed HIV infection--United States, 2008-2012. MMWR Morb Mortal Wkly Rep . 2015;64:657-662.
2. Bradley H, Hall HI, Wolitski RJ, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV--United States, 2011. MMWR Morb Mortal Wkly Rep . 2014;63:1113-1117.
3. Maulsby C, Millet G, Lindsey K, et al. HIV among black men who have sex with men (MSM) in the United States: a review of the literature. AIDS Behav . 2014;18:10-25.
4. Centers for Disease Control and Prevention. Estimated HIV incidence among adults and adolescents in the United States, 2007-2010, HIV Surveillance Supplemental Report. 2012. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/hiv/pdf/statistics_hssr_vol_17_no_4.pdf . Accessed October 8, 2015.
5. Cleary PD, Van Devanter N, Rogers TF, et al. Behavior changes after notification of HIV infection. Am J Public Health . 1991;81:1586-1590.
6. Higgins DL, Galavotti C, O’Reilly KR, et al. Evidence for the effects of HIV antibody counseling and testing on risk behaviors. JAMA . 1991;266:2419-2429.
7. Murphy EL, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med . 2001;135:17-26.
8. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4 cell strata. Ann Intern Med . 2003;138:620-626.
9. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med . 2015;373:795-807.
10. Daar ES, Pilcher CD, Hecht FM. Clinical presentation and diagnosis of primary HIV-1 infection. Curr Opin HIV AIDS . 2008;3:10-15.
11. Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med . 1988;148:945-949.
12. Moyer V, US Preventative Services Task Force. Screening for HIV: US Preventive Services Task Force recommendation statement. Ann Intern Med . 2013;159:51-60.
13. Jenkins T, Gardner E, Thrun M, et al. Risk-based HIV testing fails to detect the majority of HIV-infected persons in medical care settings. Sex Transm Dis . 2006;33:329-333.
14. Klein D, Hurley LB, Merrill D, et al. Review of medical encounters in the 5 years before a diagnosis of HIV-1 infection: implications for early detection. J Acquir Immune Defic Syndr . 2003;32:143-152.
15. Pandori M, Hackett J Jr, Louie B, et al. Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J Clin Microbiol . 2009;47:2639-2642.
16. Branson BM. The future of HIV testing. J Acquir Imm Defic Syndr . 2010;55 Suppl 2:S102-S105.
17. Grant RM, Lama JR, Anderson PL, et al; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med . 2010;363:2587-2599.
18. Baeten JM, Donnell D, Ndase P, et al; Partners PrEP Study Team. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med . 2012;367:399-410.
19. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med . 2012;367:423-434.
20. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, doubleblind, placebo-controlled phase 3 trial. Lancet . 2013;381:2083-2090.
21. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis . 2014;14:820-829.
22. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med . 2012;4:151ra125.
23. Henderson FL, Taylor AW, Chirwa LI, et al. Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana. Paper presented at International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 1922, 2015; Vancouver, Canada.
24. Murnane PM, Celum C, Mugo N, et al. Efficacy of preexposure prophylaxis for HIV-1 prevention among high-risk heterosexuals: subgroup analyses from a randomized trial. AIDS . 2013;27:2155-2160.
25. Heffron R, Mugo N, Were E, et al. Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception. AIDS . 2014;28:2771-2776.
26. Buchbinder SP, Glidden DV, Liu AY, et al. HIV pre-exposure prophylaxis in men who have sex with men and transgender women: a secondary analysis of a phase 3 randomised controlled efficacy trial. Lancet Infect Dis . 2014;14:468-475.
27. Center for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2014. Centers for Disease Control and Prevention Web site. Available at: http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf . Accessed June 18, 2015.
28. Grant RM. Scale-up of preexposure prophylaxis in San Francisco to impact HIV incidence. Abstract 25. Paper presented at Conference on Retroviruses and Opportunistic Infections; February 23-26, 2015; Seattle, WA.
29. Cohen SE, Vittinghoff E, Bacon O, et al. High interest in preexposure prophylaxis among men who have sex with men at risk for HIV infection: baseline data from the US PrEP demonstration project. J Acquir Immune Defic Syndr . 2015;68:439-448.
30. Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med . 2013;10:e1001511.
31. Gilmore H, Koester K, Liu A, et al. To PrEP or not to PrEP: Perspectives from US iPrEx open label extension (OLE) participants. Abstract 440. Paper presented at 9th International Conference on HIV Treatment and Prevention Adherence; June 9, 2014; Miami Beach, FL.
32. Jain S, Gregor C, Krakower D, et al. Attitudes and interest toward HIV pre-exposure prophylaxis (PrEP) among participants using HIV non-occupational post-exposure prophylaxis (NPEP). Poster Abstract 1523. Poster presented at Infectious Disease Society of America Conference; October 8-12, 2014; Philadelphia, PA.
33. van der Straten A, Stadler J, Luecke E, et al; VOICE-C Study Team, Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa. J Int AIDS Soc . 2014;17:19146.
34. Corneli AL, McKenna K, Headley J, et al; FEM-PrEP Study Group. A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa. J Int AIDS Soc . 2014;17:19152.
35. Krakower D, Ware N, Mitty JA, et al. HIV providers’ perceived barriers and facilitators to implementing pre-exposure prophylaxis in care settings: a qualitative study. AIDS Behav . 2014;18:1712-1721.
36. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet . 2015. [Epub ahead of print].
37. Mugwanya KK, Donnell D, Celum C, et al. Sexual behaviour of heterosexual men and women receiving antiretroviral pre-exposure prophylaxis for HIV prevention: a longitudinal analysis. Lancet Infect Dis . 2013;13:1021-1028.
38. Volk JE, Marcus JL, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis . 2015;61:1601-1603.
39. Lehman DA, Baeten JM, McCoy CO, et al. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. J Infect Dis . 2015;211:1211-1218.
40. Supervie V, Garcia-Lerma JG, Heneine W, et al. HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis. Proc Natl Acad Sci U S A . 2010;107:12381-12386.
41. AIDSinfo. Cost considerations and antiretroviral therapy. AIDSinfo Web site. Available at: https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv-guidelines/459/cost-considerations-and-antiretroviral-therapy . Accessed December 14, 2015.
42. Gomez GB, Borquez A, Case KK, et al. The cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studies. PLoS Med . 2013;10:e1001401.
43. Oldenburg CE, Perez-Brumer AG, Hatzenbuehler ML, et al. State-level structural sexual stigma and HIV prevention in a national online sample of HIV-uninfected MSM in the United States. AIDS . 2015;29:837-845.
44. Hatzenbuehler ML, O’Cleirigh C, Mayer KH, et al. Prospective associations between HIV-related stigma, transmission risk behaviors, and adverse mental health outcomes in men who have sex with men. Ann Behav Med . 2011;42:227-234.
45. Hatzenbuehler ML, Bellatorre A, Lee Y, et al. Structural stigma and all-cause mortality in sexual minority populations. Soc Sci Med . 2014;103:33-41.
46. Arnold EA, Hazelton P, Lane T, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (PrEP) in clinical settings to prevent HIV infection. PLoS One . 2012;7:e40603.
47. North Carolina AIDS Training and Education Center. For PrEP Providers. North Carolina AIDS Training and Education Center Web site. Available at: http://www.med.unc.edu/ncaidstraining/prep/for-providers/for-prep-prescribers . Accessed July 7, 2015.
48. Patel P, Borkowf CB, Brook JT, et al. Estimating per-act HIV transmission risk: a systematic review. AIDS . 2014;28:1509-1519.
49. Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and metaanalysis. Int J Epidemiol . 2014;43:235-248.
50. MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy . 2014;25:34-52.
51. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ . 2012;345:e5945.
52. Gowing L, Farrell MF, Bornemann R, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev . 2011;(8):CD004145.
53. D’Aunno T, Pollack HA, Frimpong JA, et al. Evidence-based treatment for opioid disorders: a 23-year national study of methadone dose levels. J Subst Abuse Treat . 2014;47:245-250.
